Results of a new US study show that cholesterol lowering drug rosuvastatin can considerably decrease the risk of venous thromboembolism in healthy people.
In their trials the researchers found that rosuvastatin reduced the risk of blood clots or venous thromboembolism nearly 43 percent in healthy people.
Pulmonary embolism and deep vein thrombosis are two well-known forms of VTE and they are two common reasons behind preventable death among hospital patients.
The study has been published in the New England Journal of Medicine.
In the UK, there are almost 25,000 fatal blood clotting related deaths every year and according to an estimate nearly 52 percent hospital patients in UK have higher risk for developing DVT.





















